| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staining and Labeling | 18 | 2022 | 1085 | 7.280 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 38 | 2023 | 1405 | 4.490 |
Why?
|
| Hodgkin Disease | 21 | 2020 | 1378 | 2.700 |
Why?
|
| Lymphoma, B-Cell | 17 | 2019 | 940 | 2.500 |
Why?
|
| Immunohistochemistry | 51 | 2020 | 11076 | 2.410 |
Why?
|
| Tissue Fixation | 5 | 2024 | 241 | 2.200 |
Why?
|
| Cells | 4 | 2020 | 165 | 2.090 |
Why?
|
| Tumor Microenvironment | 42 | 2024 | 3878 | 2.070 |
Why?
|
| Antibodies | 7 | 2022 | 2418 | 2.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 11 | 2016 | 988 | 1.890 |
Why?
|
| Paraffin Embedding | 5 | 2024 | 302 | 1.710 |
Why?
|
| Mediastinal Neoplasms | 9 | 2019 | 401 | 1.540 |
Why?
|
| Burkitt Lymphoma | 7 | 2022 | 335 | 1.520 |
Why?
|
| Reed-Sternberg Cells | 9 | 2019 | 72 | 1.340 |
Why?
|
| Lymphoproliferative Disorders | 8 | 2012 | 531 | 1.330 |
Why?
|
| Antigens | 3 | 2022 | 1443 | 1.210 |
Why?
|
| Cytological Techniques | 2 | 2019 | 218 | 1.150 |
Why?
|
| Protein-Tyrosine Kinases | 16 | 2019 | 2425 | 1.120 |
Why?
|
| Neoplasm Proteins | 9 | 2021 | 3617 | 1.040 |
Why?
|
| Lung Neoplasms | 29 | 2024 | 13381 | 0.990 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 15 | 2020 | 1092 | 0.980 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 21 | 2024 | 5314 | 0.950 |
Why?
|
| Chromosomes, Human, Pair 9 | 8 | 2019 | 535 | 0.890 |
Why?
|
| Melanoma | 16 | 2023 | 5709 | 0.850 |
Why?
|
| Tumor Escape | 3 | 2021 | 370 | 0.840 |
Why?
|
| Leukemia, Myeloid, Acute | 13 | 2024 | 3615 | 0.830 |
Why?
|
| Antibodies, Monoclonal | 22 | 2023 | 9177 | 0.830 |
Why?
|
| Antibodies, Neoplasm | 5 | 2016 | 281 | 0.820 |
Why?
|
| Lymphoma | 9 | 2022 | 1901 | 0.820 |
Why?
|
| T-Lymphocytes | 20 | 2024 | 10194 | 0.800 |
Why?
|
| Histiocytes | 2 | 2022 | 98 | 0.770 |
Why?
|
| Histological Techniques | 2 | 2022 | 194 | 0.760 |
Why?
|
| Lymphoma, T-Cell | 6 | 2018 | 304 | 0.760 |
Why?
|
| Galectin 1 | 6 | 2017 | 128 | 0.750 |
Why?
|
| Antigens, CD19 | 3 | 2021 | 424 | 0.750 |
Why?
|
| Antigens, Neoplasm | 10 | 2022 | 1993 | 0.740 |
Why?
|
| Frozen Sections | 2 | 2021 | 153 | 0.730 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2016 | 169 | 0.720 |
Why?
|
| Polylysine | 1 | 2020 | 131 | 0.710 |
Why?
|
| Galactosides | 1 | 2020 | 54 | 0.710 |
Why?
|
| In Situ Hybridization, Fluorescence | 12 | 2016 | 2510 | 0.710 |
Why?
|
| Immunoenzyme Techniques | 7 | 2020 | 1704 | 0.680 |
Why?
|
| Gold Colloid | 1 | 2019 | 12 | 0.680 |
Why?
|
| Histocytochemistry | 1 | 2020 | 698 | 0.670 |
Why?
|
| CD8-Positive T-Lymphocytes | 19 | 2024 | 4580 | 0.660 |
Why?
|
| Laminin | 1 | 2021 | 408 | 0.660 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2023 | 1374 | 0.660 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 13 | 2014 | 1626 | 0.650 |
Why?
|
| Horseradish Peroxidase | 1 | 2019 | 166 | 0.650 |
Why?
|
| Humans | 289 | 2024 | 761596 | 0.650 |
Why?
|
| beta-Galactosidase | 1 | 2020 | 574 | 0.640 |
Why?
|
| Gene Expression Regulation, Neoplastic | 27 | 2024 | 8554 | 0.630 |
Why?
|
| Immunotherapy | 14 | 2023 | 4652 | 0.630 |
Why?
|
| Antineoplastic Agents | 28 | 2023 | 13642 | 0.600 |
Why?
|
| Mutation | 46 | 2024 | 30053 | 0.600 |
Why?
|
| Histiocytosis, Sinus | 2 | 2016 | 45 | 0.590 |
Why?
|
| Indoles | 5 | 2020 | 1833 | 0.590 |
Why?
|
| B-Lymphocytes | 18 | 2024 | 4758 | 0.590 |
Why?
|
| Proteoglycans | 1 | 2021 | 803 | 0.590 |
Why?
|
| Lymphoma, Follicular | 5 | 2023 | 457 | 0.580 |
Why?
|
| Chromosome Aberrations | 6 | 2023 | 1768 | 0.580 |
Why?
|
| Proteins | 4 | 2023 | 6032 | 0.570 |
Why?
|
| Translocation, Genetic | 13 | 2016 | 1393 | 0.570 |
Why?
|
| Cell Line, Tumor | 53 | 2021 | 16990 | 0.570 |
Why?
|
| Bone Marrow | 8 | 2024 | 2911 | 0.570 |
Why?
|
| Adenocarcinoma | 9 | 2023 | 6345 | 0.570 |
Why?
|
| Microscopy, Fluorescence | 3 | 2021 | 2645 | 0.570 |
Why?
|
| Drug Resistance, Neoplasm | 14 | 2020 | 5305 | 0.550 |
Why?
|
| Antigens, Surface | 1 | 2021 | 1606 | 0.550 |
Why?
|
| beta 2-Microglobulin | 2 | 2018 | 329 | 0.540 |
Why?
|
| Lymphoma, Mantle-Cell | 5 | 2016 | 237 | 0.530 |
Why?
|
| TNF Receptor-Associated Factor 1 | 2 | 2007 | 48 | 0.530 |
Why?
|
| Polyomavirus Infections | 2 | 2022 | 194 | 0.530 |
Why?
|
| Proto-Oncogene Proteins c-rel | 2 | 2007 | 71 | 0.530 |
Why?
|
| Neoplasms | 22 | 2023 | 22173 | 0.520 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2016 | 27 | 0.520 |
Why?
|
| Pyrazoles | 9 | 2016 | 2009 | 0.520 |
Why?
|
| Alkaline Phosphatase | 1 | 2019 | 864 | 0.510 |
Why?
|
| Photography | 1 | 2019 | 532 | 0.510 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2013 | 4514 | 0.510 |
Why?
|
| Iodine Radioisotopes | 1 | 2019 | 1031 | 0.510 |
Why?
|
| Fluorescent Antibody Technique | 8 | 2023 | 2467 | 0.500 |
Why?
|
| Lymphoid Tissue | 3 | 2015 | 445 | 0.500 |
Why?
|
| Antibody Specificity | 2 | 2021 | 1060 | 0.500 |
Why?
|
| Protein Kinase Inhibitors | 19 | 2017 | 5672 | 0.490 |
Why?
|
| Pathology, Surgical | 1 | 2016 | 151 | 0.480 |
Why?
|
| Cell Adhesion | 6 | 2020 | 3088 | 0.480 |
Why?
|
| HLA Antigens | 3 | 2022 | 1328 | 0.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2023 | 11742 | 0.470 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2020 | 2547 | 0.460 |
Why?
|
| Collagen | 2 | 2021 | 2638 | 0.460 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2022 | 328 | 0.450 |
Why?
|
| Gene Rearrangement | 7 | 2018 | 1125 | 0.450 |
Why?
|
| Transcription Factor AP-1 | 4 | 2012 | 321 | 0.440 |
Why?
|
| Janus Kinase 2 | 8 | 2015 | 560 | 0.440 |
Why?
|
| Vulvar Neoplasms | 1 | 2016 | 263 | 0.440 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 12 | 2023 | 5672 | 0.430 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 2023 | 545 | 0.430 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 1668 | 0.430 |
Why?
|
| Oncogene Proteins, Fusion | 8 | 2016 | 1609 | 0.430 |
Why?
|
| Fluorescent Dyes | 1 | 2021 | 1903 | 0.430 |
Why?
|
| Gene Expression | 9 | 2016 | 7581 | 0.420 |
Why?
|
| Coloring Agents | 3 | 2019 | 562 | 0.400 |
Why?
|
| Animals | 91 | 2024 | 168475 | 0.400 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2024 | 4024 | 0.400 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2021 | 1349 | 0.400 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2014 | 168 | 0.390 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2015 | 2872 | 0.390 |
Why?
|
| Antigens, CD | 8 | 2014 | 4001 | 0.380 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2022 | 2688 | 0.380 |
Why?
|
| Microscopy | 3 | 2023 | 903 | 0.380 |
Why?
|
| Genes, myc | 3 | 2013 | 390 | 0.380 |
Why?
|
| Gene Expression Profiling | 21 | 2024 | 9420 | 0.370 |
Why?
|
| Pre-B Cell Receptors | 1 | 2010 | 3 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2012 | 571 | 0.370 |
Why?
|
| Hematologic Neoplasms | 3 | 2023 | 1896 | 0.360 |
Why?
|
| Immunophenotyping | 10 | 2024 | 1869 | 0.360 |
Why?
|
| Sarcoidosis | 1 | 2016 | 521 | 0.350 |
Why?
|
| Flow Cytometry | 16 | 2023 | 5870 | 0.350 |
Why?
|
| Pyridines | 7 | 2014 | 2875 | 0.350 |
Why?
|
| Gene Dosage | 5 | 2016 | 1218 | 0.340 |
Why?
|
| Molecular Targeted Therapy | 7 | 2021 | 2811 | 0.340 |
Why?
|
| Protein Binding | 8 | 2021 | 9353 | 0.340 |
Why?
|
| Cytokines | 11 | 2019 | 7396 | 0.340 |
Why?
|
| Female | 125 | 2024 | 392705 | 0.340 |
Why?
|
| Tumor Virus Infections | 1 | 2012 | 438 | 0.340 |
Why?
|
| Receptor, Notch1 | 2 | 2013 | 496 | 0.330 |
Why?
|
| Myeloproliferative Disorders | 5 | 2023 | 613 | 0.330 |
Why?
|
| Waldenstrom Macroglobulinemia | 6 | 2015 | 1073 | 0.330 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2023 | 1394 | 0.320 |
Why?
|
| Middle Aged | 84 | 2024 | 220921 | 0.320 |
Why?
|
| Pyrimidines | 6 | 2021 | 3028 | 0.320 |
Why?
|
| Receptors, Cytokine | 3 | 2012 | 258 | 0.320 |
Why?
|
| Karyopherins | 3 | 2015 | 133 | 0.320 |
Why?
|
| Skin Neoplasms | 7 | 2023 | 5821 | 0.320 |
Why?
|
| Formaldehyde | 3 | 2024 | 358 | 0.310 |
Why?
|
| Silver | 2 | 2019 | 117 | 0.310 |
Why?
|
| Intestinal Neoplasms | 2 | 2023 | 314 | 0.310 |
Why?
|
| Nuclear Proteins | 13 | 2023 | 5799 | 0.310 |
Why?
|
| Macrophages | 12 | 2024 | 5767 | 0.310 |
Why?
|
| Aged | 70 | 2024 | 169310 | 0.310 |
Why?
|
| Angiopoietin-2 | 2 | 2021 | 173 | 0.310 |
Why?
|
| Amino Acid Substitution | 2 | 2016 | 1739 | 0.310 |
Why?
|
| Male | 110 | 2024 | 360846 | 0.300 |
Why?
|
| Neoplasm Staging | 19 | 2021 | 11120 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2023 | 9280 | 0.290 |
Why?
|
| Neurofibromin 1 | 2 | 2021 | 190 | 0.290 |
Why?
|
| Prognosis | 27 | 2024 | 29629 | 0.290 |
Why?
|
| Bone Marrow Examination | 4 | 2015 | 155 | 0.290 |
Why?
|
| Mice | 68 | 2024 | 81539 | 0.290 |
Why?
|
| Cells, Cultured | 8 | 2021 | 18966 | 0.280 |
Why?
|
| Cancer Vaccines | 3 | 2021 | 1051 | 0.280 |
Why?
|
| Lymphocytes | 4 | 2021 | 2612 | 0.280 |
Why?
|
| Interferon-gamma | 9 | 2020 | 3162 | 0.280 |
Why?
|
| Signal Transduction | 29 | 2023 | 23447 | 0.280 |
Why?
|
| Aged, 80 and over | 37 | 2024 | 58984 | 0.280 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2008 | 164 | 0.280 |
Why?
|
| Hydroxamic Acids | 3 | 2016 | 481 | 0.280 |
Why?
|
| Glioblastoma | 5 | 2023 | 3483 | 0.280 |
Why?
|
| Dendritic Cells | 3 | 2023 | 2747 | 0.270 |
Why?
|
| Xenograft Model Antitumor Assays | 17 | 2021 | 3605 | 0.270 |
Why?
|
| Neoplasm Metastasis | 11 | 2024 | 4915 | 0.270 |
Why?
|
| Germinal Center | 5 | 2012 | 380 | 0.270 |
Why?
|
| BRCA1 Protein | 5 | 2020 | 1158 | 0.270 |
Why?
|
| Substrate Specificity | 3 | 2020 | 1791 | 0.270 |
Why?
|
| B-Lymphocyte Subsets | 4 | 2012 | 239 | 0.270 |
Why?
|
| Adult | 70 | 2024 | 221210 | 0.260 |
Why?
|
| Spleen | 7 | 2012 | 2295 | 0.260 |
Why?
|
| Myeloid Differentiation Factor 88 | 3 | 2023 | 587 | 0.260 |
Why?
|
| Mouth Neoplasms | 2 | 2022 | 596 | 0.260 |
Why?
|
| Lymphocyte Subsets | 2 | 2019 | 309 | 0.260 |
Why?
|
| Leukemia, Myeloid | 2 | 2021 | 694 | 0.260 |
Why?
|
| Biopsy | 10 | 2024 | 6766 | 0.260 |
Why?
|
| Stomach Neoplasms | 3 | 2023 | 1459 | 0.260 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2023 | 3080 | 0.260 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2005 | 64 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2014 | 2457 | 0.250 |
Why?
|
| Head and Neck Neoplasms | 4 | 2024 | 2894 | 0.250 |
Why?
|
| Cell Proliferation | 23 | 2021 | 10451 | 0.250 |
Why?
|
| Membrane Glycoproteins | 3 | 2010 | 3701 | 0.250 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2012 | 938 | 0.250 |
Why?
|
| Mutation, Missense | 3 | 2023 | 2571 | 0.250 |
Why?
|
| Interferons | 3 | 2020 | 706 | 0.250 |
Why?
|
| Genomics | 10 | 2024 | 5821 | 0.240 |
Why?
|
| Gene Amplification | 5 | 2020 | 1089 | 0.240 |
Why?
|
| Multiple Myeloma | 9 | 2016 | 5146 | 0.240 |
Why?
|
| Triazoles | 4 | 2015 | 903 | 0.240 |
Why?
|
| Salvage Therapy | 4 | 2021 | 1263 | 0.240 |
Why?
|
| Neuroendocrine Tumors | 2 | 2023 | 641 | 0.240 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2015 | 858 | 0.240 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2015 | 610 | 0.240 |
Why?
|
| Reticulin | 2 | 2014 | 19 | 0.240 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2016 | 774 | 0.240 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2022 | 4369 | 0.240 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2018 | 1435 | 0.240 |
Why?
|
| Lymphocyte Activation | 11 | 2020 | 5485 | 0.230 |
Why?
|
| Epitopes | 2 | 2021 | 2503 | 0.230 |
Why?
|
| Pleural Neoplasms | 3 | 2016 | 609 | 0.230 |
Why?
|
| Single-Cell Analysis | 4 | 2024 | 2451 | 0.230 |
Why?
|
| Cell Cycle | 7 | 2016 | 2932 | 0.230 |
Why?
|
| Oncogenes | 4 | 2013 | 1222 | 0.220 |
Why?
|
| Zebrafish | 6 | 2021 | 3008 | 0.220 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 2020 | 0.220 |
Why?
|
| Cell Nucleus | 4 | 2013 | 2910 | 0.220 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2017 | 655 | 0.220 |
Why?
|
| Fourier Analysis | 1 | 2024 | 441 | 0.220 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2016 | 262 | 0.220 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2021 | 1115 | 0.220 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2021 | 423 | 0.220 |
Why?
|
| Protein Isoforms | 3 | 2017 | 1699 | 0.220 |
Why?
|
| Biological Products | 3 | 2021 | 914 | 0.210 |
Why?
|
| Observer Variation | 4 | 2016 | 2606 | 0.210 |
Why?
|
| Herpesvirus 4, Human | 4 | 2013 | 1078 | 0.210 |
Why?
|
| HSP90 Heat-Shock Proteins | 3 | 2016 | 424 | 0.210 |
Why?
|
| Leiomyosarcoma | 2 | 2017 | 422 | 0.210 |
Why?
|
| Mesothelioma | 3 | 2016 | 807 | 0.210 |
Why?
|
| Enzyme Activation | 7 | 2015 | 3597 | 0.210 |
Why?
|
| Carcinoma | 3 | 2023 | 2330 | 0.210 |
Why?
|
| Spheroplasts | 1 | 2022 | 6 | 0.210 |
Why?
|
| Boronic Acids | 3 | 2012 | 915 | 0.210 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 117 | 0.210 |
Why?
|
| Janus Kinase 3 | 2 | 2015 | 76 | 0.200 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2016 | 612 | 0.200 |
Why?
|
| Specimen Handling | 2 | 2020 | 702 | 0.200 |
Why?
|
| Immunomodulation | 2 | 2016 | 549 | 0.200 |
Why?
|
| Receptors, CXCR4 | 4 | 2019 | 727 | 0.200 |
Why?
|
| Mice, SCID | 11 | 2016 | 2626 | 0.200 |
Why?
|
| Nocardia Infections | 1 | 2001 | 19 | 0.200 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2023 | 954 | 0.200 |
Why?
|
| Angiomyolipoma | 1 | 2023 | 187 | 0.200 |
Why?
|
| Chemotaxis, Leukocyte | 3 | 2019 | 662 | 0.190 |
Why?
|
| Bone Marrow Cells | 6 | 2015 | 2417 | 0.190 |
Why?
|
| NF-kappa B | 4 | 2015 | 2490 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2016 | 2827 | 0.190 |
Why?
|
| Xanthenes | 1 | 2021 | 72 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 3 | 2016 | 191 | 0.190 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2020 | 1469 | 0.190 |
Why?
|
| Sulfonamides | 4 | 2021 | 1979 | 0.190 |
Why?
|
| Enhancer Elements, Genetic | 4 | 2016 | 1363 | 0.190 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2021 | 340 | 0.190 |
Why?
|
| Pyrazines | 3 | 2012 | 1202 | 0.190 |
Why?
|
| Splenic Diseases | 1 | 2001 | 90 | 0.180 |
Why?
|
| Sirolimus | 6 | 2021 | 1533 | 0.180 |
Why?
|
| Reproducibility of Results | 7 | 2023 | 20100 | 0.180 |
Why?
|
| Blotting, Western | 9 | 2019 | 5035 | 0.180 |
Why?
|
| Recurrence | 12 | 2023 | 8466 | 0.180 |
Why?
|
| Microsatellite Instability | 4 | 2020 | 716 | 0.180 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2021 | 651 | 0.180 |
Why?
|
| Rhodamines | 1 | 2021 | 178 | 0.180 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2019 | 2865 | 0.180 |
Why?
|
| Fluorescein | 1 | 2021 | 175 | 0.180 |
Why?
|
| Centrifugation | 1 | 2020 | 122 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2016 | 2917 | 0.180 |
Why?
|
| Zebrafish Proteins | 2 | 2019 | 1015 | 0.180 |
Why?
|
| Glutaral | 1 | 2020 | 76 | 0.180 |
Why?
|
| Immunoglobulins | 3 | 2019 | 852 | 0.180 |
Why?
|
| Pyridinium Compounds | 2 | 2017 | 81 | 0.180 |
Why?
|
| Diagnosis, Differential | 8 | 2019 | 12973 | 0.180 |
Why?
|
| Genes, p53 | 2 | 2013 | 712 | 0.180 |
Why?
|
| Neoplasms, Muscle Tissue | 2 | 2010 | 67 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 3 | 2023 | 5368 | 0.170 |
Why?
|
| Trans-Activators | 6 | 2019 | 2856 | 0.170 |
Why?
|
| Testicular Neoplasms | 2 | 2017 | 799 | 0.170 |
Why?
|
| DNA Mutational Analysis | 6 | 2020 | 4111 | 0.170 |
Why?
|
| Anus Neoplasms | 1 | 2024 | 329 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2022 | 1745 | 0.170 |
Why?
|
| Stem Cell Transplantation | 3 | 2017 | 1600 | 0.170 |
Why?
|
| Calorimetry | 1 | 2020 | 129 | 0.170 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2014 | 382 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 3 | 2018 | 1351 | 0.170 |
Why?
|
| Mice, Inbred NOD | 9 | 2016 | 1827 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2021 | 6484 | 0.170 |
Why?
|
| 3,3'-Diaminobenzidine | 1 | 2019 | 5 | 0.170 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2024 | 738 | 0.170 |
Why?
|
| Receptors, Chemokine | 1 | 2002 | 652 | 0.170 |
Why?
|
| Indicators and Reagents | 1 | 2020 | 462 | 0.170 |
Why?
|
| Chromogenic Compounds | 1 | 2019 | 31 | 0.170 |
Why?
|
| Cell Survival | 8 | 2021 | 5791 | 0.170 |
Why?
|
| Phosphorylcholine | 2 | 2010 | 153 | 0.170 |
Why?
|
| Oncolytic Viruses | 1 | 2023 | 344 | 0.170 |
Why?
|
| Benzimidazoles | 3 | 2015 | 858 | 0.170 |
Why?
|
| Nucleic Acids | 1 | 2022 | 188 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 5 | 2023 | 2828 | 0.160 |
Why?
|
| Neoplasm, Residual | 3 | 2016 | 1008 | 0.160 |
Why?
|
| Tissue Culture Techniques | 1 | 2020 | 290 | 0.160 |
Why?
|
| Breast Neoplasms | 11 | 2024 | 21019 | 0.160 |
Why?
|
| Predictive Value of Tests | 8 | 2018 | 15266 | 0.160 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 328 | 0.160 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2013 | 1136 | 0.160 |
Why?
|
| Up-Regulation | 6 | 2019 | 4125 | 0.160 |
Why?
|
| Glycoproteins | 1 | 2006 | 2203 | 0.160 |
Why?
|
| Pyrrolidines | 3 | 2015 | 338 | 0.160 |
Why?
|
| Colorectal Neoplasms | 4 | 2021 | 6938 | 0.160 |
Why?
|
| Phenotype | 8 | 2024 | 16592 | 0.160 |
Why?
|
| Cytophotometry | 1 | 2018 | 8 | 0.160 |
Why?
|
| Survival Analysis | 7 | 2023 | 10090 | 0.160 |
Why?
|
| Cyclin D1 | 2 | 2013 | 451 | 0.160 |
Why?
|
| Killer Cells, Natural | 4 | 2022 | 2201 | 0.160 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2013 | 1062 | 0.150 |
Why?
|
| DNA Copy Number Variations | 6 | 2019 | 2020 | 0.150 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2019 | 101 | 0.150 |
Why?
|
| Antibodies, Blocking | 1 | 2019 | 243 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2017 | 1640 | 0.150 |
Why?
|
| Tissue Array Analysis | 4 | 2012 | 550 | 0.150 |
Why?
|
| Receptors, Interferon | 1 | 1998 | 116 | 0.150 |
Why?
|
| Enteropathy-Associated T-Cell Lymphoma | 2 | 2014 | 13 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2022 | 3639 | 0.150 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2010 | 226 | 0.150 |
Why?
|
| Uterine Neoplasms | 2 | 2017 | 1420 | 0.150 |
Why?
|
| Immune Evasion | 2 | 2019 | 363 | 0.150 |
Why?
|
| Cell Movement | 6 | 2013 | 5205 | 0.150 |
Why?
|
| Forkhead Transcription Factors | 6 | 2022 | 1616 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2009 | 287 | 0.150 |
Why?
|
| Herpesvirus 1, Human | 1 | 2023 | 753 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2017 | 916 | 0.150 |
Why?
|
| Leukemia, Lymphoid | 1 | 2018 | 310 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 8 | 2022 | 6131 | 0.150 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 516 | 0.150 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2022 | 541 | 0.150 |
Why?
|
| Immunoconjugates | 3 | 2016 | 953 | 0.150 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 732 | 0.150 |
Why?
|
| Cell Lineage | 5 | 2016 | 2557 | 0.150 |
Why?
|
| Apoptosis | 16 | 2022 | 9490 | 0.150 |
Why?
|
| Transcription, Genetic | 7 | 2018 | 7593 | 0.150 |
Why?
|
| Melanoma, Experimental | 2 | 2019 | 561 | 0.140 |
Why?
|
| Phosphorylation | 6 | 2015 | 8321 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 4576 | 0.140 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2023 | 3165 | 0.140 |
Why?
|
| Survival Rate | 13 | 2020 | 12723 | 0.140 |
Why?
|
| Histones | 4 | 2023 | 2580 | 0.140 |
Why?
|
| Ovarian Neoplasms | 3 | 2020 | 4878 | 0.140 |
Why?
|
| Treatment Outcome | 28 | 2023 | 64685 | 0.140 |
Why?
|
| Molecular Imaging | 2 | 2022 | 815 | 0.140 |
Why?
|
| Endogenous Retroviruses | 1 | 2018 | 111 | 0.140 |
Why?
|
| Disease Models, Animal | 13 | 2021 | 18255 | 0.140 |
Why?
|
| Immunoblastic Lymphadenopathy | 2 | 2014 | 40 | 0.140 |
Why?
|
| Cohort Studies | 18 | 2022 | 41495 | 0.140 |
Why?
|
| Thiophenes | 1 | 2021 | 569 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 2 | 2024 | 2021 | 0.140 |
Why?
|
| Acetylcysteine | 2 | 2016 | 260 | 0.140 |
Why?
|
| Simian immunodeficiency virus | 1 | 2022 | 809 | 0.140 |
Why?
|
| Brain Neoplasms | 3 | 2024 | 9032 | 0.140 |
Why?
|
| Resorcinols | 1 | 2016 | 41 | 0.140 |
Why?
|
| Embryo, Nonmammalian | 2 | 2019 | 906 | 0.140 |
Why?
|
| Estrogen Receptor alpha | 2 | 2019 | 583 | 0.140 |
Why?
|
| Immunity | 3 | 2018 | 996 | 0.130 |
Why?
|
| Primary Myelofibrosis | 2 | 2015 | 209 | 0.130 |
Why?
|
| Transplantation, Autologous | 5 | 2020 | 2115 | 0.130 |
Why?
|
| Viral Matrix Proteins | 3 | 2012 | 196 | 0.130 |
Why?
|
| Immunologic Memory | 2 | 2021 | 1359 | 0.130 |
Why?
|
| Th17 Cells | 1 | 2023 | 794 | 0.130 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2016 | 25 | 0.130 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 784 | 0.130 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 428 | 0.130 |
Why?
|
| Immunity, Innate | 2 | 2018 | 3066 | 0.130 |
Why?
|
| Kidney Neoplasms | 2 | 2023 | 4251 | 0.130 |
Why?
|
| Interleukin-2 | 2 | 2022 | 1889 | 0.130 |
Why?
|
| DNA-Binding Proteins | 10 | 2015 | 9610 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2017 | 3492 | 0.130 |
Why?
|
| Ribosomal Proteins | 2 | 2016 | 371 | 0.130 |
Why?
|
| Autoimmunity | 2 | 2016 | 1356 | 0.130 |
Why?
|
| Virus Diseases | 1 | 2022 | 718 | 0.130 |
Why?
|
| Vincristine | 2 | 2016 | 1036 | 0.130 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2010 | 740 | 0.130 |
Why?
|
| Disease-Free Survival | 8 | 2019 | 6815 | 0.130 |
Why?
|
| Biopsy, Needle | 1 | 2020 | 1626 | 0.130 |
Why?
|
| Transcription Factors | 7 | 2021 | 12130 | 0.130 |
Why?
|
| Neuroblastoma | 3 | 2012 | 1250 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2013 | 946 | 0.120 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2015 | 111 | 0.120 |
Why?
|
| Cell Differentiation | 11 | 2023 | 11530 | 0.120 |
Why?
|
| Retrospective Studies | 20 | 2024 | 80647 | 0.120 |
Why?
|
| U937 Cells | 1 | 2015 | 261 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 4 | 2015 | 6075 | 0.120 |
Why?
|
| DNA Polymerase II | 1 | 2015 | 104 | 0.120 |
Why?
|
| Repressor Proteins | 2 | 2019 | 2986 | 0.120 |
Why?
|
| Pseudogenes | 1 | 2015 | 104 | 0.120 |
Why?
|
| Paraffin | 1 | 2014 | 36 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2017 | 10766 | 0.120 |
Why?
|
| Receptors, Laminin | 1 | 2014 | 26 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2015 | 212 | 0.120 |
Why?
|
| Diagnostic Imaging | 3 | 2024 | 3530 | 0.120 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2014 | 33 | 0.120 |
Why?
|
| Isoxazoles | 1 | 2016 | 232 | 0.120 |
Why?
|
| HL-60 Cells | 1 | 2015 | 363 | 0.120 |
Why?
|
| Dioxygenases | 2 | 2014 | 345 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2021 | 2048 | 0.120 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2015 | 1551 | 0.120 |
Why?
|
| Young Adult | 19 | 2022 | 59260 | 0.120 |
Why?
|
| Disease Progression | 14 | 2019 | 13510 | 0.120 |
Why?
|
| DNA, Bacterial | 2 | 2017 | 1479 | 0.120 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2015 | 285 | 0.120 |
Why?
|
| Leukemia, T-Cell | 1 | 2014 | 101 | 0.120 |
Why?
|
| Transcription Factor RelA | 1 | 2015 | 254 | 0.120 |
Why?
|
| Antigen Presentation | 2 | 2018 | 1251 | 0.120 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2016 | 368 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 694 | 0.120 |
Why?
|
| Hot Temperature | 1 | 2021 | 1440 | 0.120 |
Why?
|
| Transplantation, Homologous | 7 | 2022 | 4807 | 0.120 |
Why?
|
| Integrin alpha Chains | 1 | 2014 | 95 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 1129 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 1406 | 0.110 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2013 | 436 | 0.110 |
Why?
|
| Palatine Tonsil | 2 | 2024 | 193 | 0.110 |
Why?
|
| Combined Modality Therapy | 4 | 2022 | 8527 | 0.110 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2014 | 48 | 0.110 |
Why?
|
| Azepines | 2 | 2013 | 329 | 0.110 |
Why?
|
| Proteomics | 2 | 2024 | 3848 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 16 | 2019 | 22174 | 0.110 |
Why?
|
| BRCA2 Protein | 2 | 2016 | 805 | 0.110 |
Why?
|
| Hydrazines | 1 | 2015 | 224 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2013 | 19 | 0.110 |
Why?
|
| Quinazolines | 4 | 2013 | 1371 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2012 | 1974 | 0.110 |
Why?
|
| Pneumonia | 2 | 2023 | 2143 | 0.110 |
Why?
|
| Drug Synergism | 5 | 2021 | 1757 | 0.110 |
Why?
|
| Prednisone | 2 | 2016 | 1563 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2010 | 1802 | 0.110 |
Why?
|
| Receptors, Immunologic | 3 | 2020 | 1410 | 0.110 |
Why?
|
| Polymers | 1 | 2020 | 1616 | 0.110 |
Why?
|
| Oxygen | 2 | 2015 | 4227 | 0.110 |
Why?
|
| Nuclear Export Signals | 1 | 2012 | 9 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2020 | 3359 | 0.100 |
Why?
|
| Adenosine | 2 | 2015 | 808 | 0.100 |
Why?
|
| Cell Transformation, Viral | 2 | 2012 | 526 | 0.100 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2012 | 40 | 0.100 |
Why?
|
| ran GTP-Binding Protein | 1 | 2012 | 53 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 125 | 0.100 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2018 | 491 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 1728 | 0.100 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2019 | 783 | 0.100 |
Why?
|
| Intestine, Small | 1 | 2018 | 1206 | 0.100 |
Why?
|
| Lymph Nodes | 4 | 2024 | 3465 | 0.100 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2016 | 634 | 0.100 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2013 | 122 | 0.100 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2014 | 179 | 0.100 |
Why?
|
| Cell Cycle Proteins | 5 | 2016 | 3449 | 0.100 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 2011 | 25 | 0.100 |
Why?
|
| Retinol-Binding Proteins, Cellular | 1 | 2011 | 12 | 0.100 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2012 | 257 | 0.100 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2001 | 1228 | 0.100 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 1613 | 0.100 |
Why?
|
| Retinoblastoma Protein | 2 | 2015 | 672 | 0.100 |
Why?
|
| Fetal Proteins | 1 | 2012 | 98 | 0.100 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2012 | 427 | 0.100 |
Why?
|
| Mucous Membrane | 1 | 2015 | 659 | 0.100 |
Why?
|
| Antigen-Presenting Cells | 3 | 2022 | 964 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2016 | 1784 | 0.100 |
Why?
|
| Dexamethasone | 2 | 2018 | 1948 | 0.100 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2012 | 57 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 615 | 0.100 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 478 | 0.100 |
Why?
|
| Genetic Fitness | 1 | 2012 | 115 | 0.100 |
Why?
|
| Receptors, Virus | 2 | 2016 | 640 | 0.100 |
Why?
|
| Autocrine Communication | 1 | 2012 | 169 | 0.100 |
Why?
|
| Immunologic Surveillance | 1 | 2012 | 92 | 0.100 |
Why?
|
| Aminopyridines | 1 | 2015 | 573 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2016 | 2224 | 0.090 |
Why?
|
| Herpesvirus 8, Human | 1 | 2013 | 255 | 0.090 |
Why?
|
| Plasmacytoma | 1 | 2012 | 171 | 0.090 |
Why?
|
| Mice, Knockout | 12 | 2015 | 14417 | 0.090 |
Why?
|
| Haploinsufficiency | 1 | 2013 | 337 | 0.090 |
Why?
|
| Fibrosis | 2 | 2015 | 2049 | 0.090 |
Why?
|
| Barrett Esophagus | 1 | 2015 | 492 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 4 | 2016 | 2645 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 1745 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 2016 | 526 | 0.090 |
Why?
|
| Sp1 Transcription Factor | 1 | 2011 | 140 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 726 | 0.090 |
Why?
|
| YY1 Transcription Factor | 1 | 2011 | 60 | 0.090 |
Why?
|
| Receptor, erbB-2 | 2 | 2019 | 2557 | 0.090 |
Why?
|
| Anemia, Aplastic | 1 | 2013 | 230 | 0.090 |
Why?
|
| Self Tolerance | 1 | 2011 | 123 | 0.090 |
Why?
|
| Gene Expression Regulation | 6 | 2014 | 11904 | 0.090 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2013 | 245 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 619 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 7 | 2015 | 6214 | 0.090 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2024 | 373 | 0.090 |
Why?
|
| Urologic Neoplasms | 1 | 2014 | 314 | 0.090 |
Why?
|
| Ligands | 4 | 2022 | 3272 | 0.090 |
Why?
|
| CDC2 Protein Kinase | 1 | 2011 | 213 | 0.090 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 507 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 2014 | 951 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2018 | 2805 | 0.090 |
Why?
|
| Clone Cells | 2 | 2011 | 1659 | 0.090 |
Why?
|
| Adolescent | 12 | 2024 | 88326 | 0.090 |
Why?
|
| Tissue Adhesions | 1 | 2011 | 218 | 0.090 |
Why?
|
| Western World | 1 | 2009 | 27 | 0.090 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2010 | 86 | 0.080 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2010 | 80 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2012 | 535 | 0.080 |
Why?
|
| Gene Library | 1 | 2012 | 1059 | 0.080 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2012 | 504 | 0.080 |
Why?
|
| Cytosine | 1 | 2011 | 211 | 0.080 |
Why?
|
| Cell Tracking | 1 | 2011 | 139 | 0.080 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2010 | 129 | 0.080 |
Why?
|
| Thalidomide | 2 | 2014 | 885 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2010 | 410 | 0.080 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 8002 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 14665 | 0.080 |
Why?
|
| Mice, Nude | 4 | 2019 | 3614 | 0.080 |
Why?
|
| Meninges | 1 | 2011 | 198 | 0.080 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 909 | 0.080 |
Why?
|
| Remission Induction | 4 | 2019 | 2397 | 0.080 |
Why?
|
| Abdominal Neoplasms | 1 | 2010 | 287 | 0.080 |
Why?
|
| Genetic Loci | 2 | 2015 | 2632 | 0.080 |
Why?
|
| RecQ Helicases | 1 | 2009 | 53 | 0.080 |
Why?
|
| Gene Silencing | 2 | 2013 | 1509 | 0.080 |
Why?
|
| Microarray Analysis | 1 | 2012 | 750 | 0.080 |
Why?
|
| Neutrophils | 1 | 2021 | 3767 | 0.080 |
Why?
|
| TRPC Cation Channels | 1 | 2009 | 111 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 2220 | 0.080 |
Why?
|
| Urea | 1 | 2011 | 443 | 0.080 |
Why?
|
| Transcriptional Activation | 2 | 2012 | 1756 | 0.080 |
Why?
|
| Cytogenetic Analysis | 1 | 2009 | 270 | 0.080 |
Why?
|
| Chemokine CXCL12 | 1 | 2010 | 454 | 0.080 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2011 | 353 | 0.080 |
Why?
|
| Gene Targeting | 2 | 2010 | 838 | 0.080 |
Why?
|
| Breast | 2 | 2015 | 1967 | 0.080 |
Why?
|
| Base Sequence | 6 | 2019 | 12441 | 0.080 |
Why?
|
| Lymphopoiesis | 1 | 2009 | 133 | 0.080 |
Why?
|
| Lipocalins | 1 | 2009 | 161 | 0.080 |
Why?
|
| Reproduction | 1 | 2012 | 645 | 0.070 |
Why?
|
| Piperidines | 4 | 2020 | 1656 | 0.070 |
Why?
|
| Tumor Burden | 4 | 2015 | 1892 | 0.070 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2010 | 236 | 0.070 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 719 | 0.070 |
Why?
|
| Acute-Phase Proteins | 1 | 2009 | 250 | 0.070 |
Why?
|
| Base Pairing | 1 | 2008 | 140 | 0.070 |
Why?
|
| Lectins, C-Type | 1 | 2011 | 585 | 0.070 |
Why?
|
| Oocytes | 1 | 2012 | 1166 | 0.070 |
Why?
|
| Epithelial Cells | 3 | 2022 | 3677 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 4317 | 0.070 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2009 | 647 | 0.070 |
Why?
|
| Indolizines | 2 | 2017 | 30 | 0.070 |
Why?
|
| Drug Administration Schedule | 4 | 2017 | 4853 | 0.070 |
Why?
|
| Cyclic N-Oxides | 2 | 2017 | 72 | 0.070 |
Why?
|
| Mice, Transgenic | 7 | 2013 | 9542 | 0.070 |
Why?
|
| Rectal Neoplasms | 1 | 2016 | 1157 | 0.070 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2010 | 305 | 0.070 |
Why?
|
| Histone Deacetylases | 1 | 2012 | 720 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2022 | 3733 | 0.070 |
Why?
|
| Glioma | 1 | 2022 | 3455 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2012 | 1113 | 0.070 |
Why?
|
| Cell Line | 7 | 2019 | 15601 | 0.070 |
Why?
|
| Protein Transport | 1 | 2012 | 1967 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2019 | 2223 | 0.070 |
Why?
|
| Liposarcoma | 1 | 2009 | 289 | 0.070 |
Why?
|
| Phosphoproteins | 2 | 2012 | 2448 | 0.070 |
Why?
|
| Papillomaviridae | 2 | 2024 | 1119 | 0.070 |
Why?
|
| Genotype | 4 | 2015 | 12990 | 0.070 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 1366 | 0.070 |
Why?
|
| Cadherins | 1 | 2011 | 903 | 0.070 |
Why?
|
| Myeloid Cells | 1 | 2011 | 823 | 0.070 |
Why?
|
| Chemokines | 2 | 2023 | 959 | 0.070 |
Why?
|
| Meningioma | 1 | 2015 | 1218 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2015 | 3687 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2006 | 287 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2022 | 664 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2010 | 3415 | 0.070 |
Why?
|
| Integrins | 1 | 2010 | 834 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinase | 2 | 2019 | 126 | 0.060 |
Why?
|
| Molecular Sequence Data | 7 | 2015 | 17635 | 0.060 |
Why?
|
| Tissue Distribution | 3 | 2017 | 2264 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 1248 | 0.060 |
Why?
|
| Fusobacterium nucleatum | 2 | 2017 | 179 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2010 | 1510 | 0.060 |
Why?
|
| RNA-Binding Proteins | 2 | 2011 | 1898 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 1334 | 0.060 |
Why?
|
| DNA | 2 | 2024 | 7213 | 0.060 |
Why?
|
| Adenine | 3 | 2016 | 987 | 0.060 |
Why?
|
| Aspirin | 1 | 2017 | 3133 | 0.060 |
Why?
|
| HIV Infections | 3 | 2022 | 17354 | 0.060 |
Why?
|
| Genes, Neoplasm | 2 | 2018 | 370 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 1076 | 0.060 |
Why?
|
| Multiple Sclerosis | 2 | 2011 | 3222 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 2057 | 0.060 |
Why?
|
| RNA | 1 | 2015 | 2725 | 0.060 |
Why?
|
| Genetic Variation | 3 | 2016 | 6567 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 1654 | 0.060 |
Why?
|
| Anemia | 2 | 2012 | 1509 | 0.060 |
Why?
|
| Retreatment | 2 | 2016 | 598 | 0.060 |
Why?
|
| Pyrroles | 1 | 2011 | 1125 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2012 | 1995 | 0.060 |
Why?
|
| Spectrometry, Mass, Secondary Ion | 1 | 2024 | 15 | 0.060 |
Why?
|
| Genomic Instability | 1 | 2009 | 709 | 0.060 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2012 | 855 | 0.060 |
Why?
|
| Indazoles | 2 | 2020 | 304 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2009 | 937 | 0.060 |
Why?
|
| Immunoglobulin M | 3 | 2015 | 1526 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 2539 | 0.060 |
Why?
|
| Mycosis Fungoides | 2 | 2016 | 170 | 0.060 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2009 | 499 | 0.060 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 491 | 0.060 |
Why?
|
| STAT Transcription Factors | 2 | 2014 | 188 | 0.060 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2023 | 87 | 0.060 |
Why?
|
| Vacuum | 1 | 2023 | 65 | 0.060 |
Why?
|
| Drug Approval | 1 | 2010 | 814 | 0.050 |
Why?
|
| Embryonic Stem Cells | 1 | 2011 | 1263 | 0.050 |
Why?
|
| Point Mutation | 1 | 2009 | 1595 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2011 | 1336 | 0.050 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 2 | 2014 | 86 | 0.050 |
Why?
|
| Graft Survival | 2 | 2011 | 3820 | 0.050 |
Why?
|
| Mitochondria | 1 | 2016 | 3624 | 0.050 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2012 | 1390 | 0.050 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2002 | 121 | 0.050 |
Why?
|
| Massachusetts | 1 | 2016 | 8833 | 0.050 |
Why?
|
| Chemokine CCL20 | 1 | 2002 | 64 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2006 | 592 | 0.050 |
Why?
|
| Receptors, CCR6 | 1 | 2002 | 74 | 0.050 |
Why?
|
| Prediabetic State | 1 | 2008 | 545 | 0.050 |
Why?
|
| DNA Viruses | 1 | 2022 | 34 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 3032 | 0.050 |
Why?
|
| Adipocytes | 1 | 2009 | 1194 | 0.050 |
Why?
|
| Interleukin-4 | 3 | 2015 | 1149 | 0.050 |
Why?
|
| Nocardia | 1 | 2001 | 9 | 0.050 |
Why?
|
| Lymphocyte Count | 2 | 2016 | 778 | 0.050 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2022 | 153 | 0.050 |
Why?
|
| Exons | 1 | 2008 | 2391 | 0.050 |
Why?
|
| Chemokines, CC | 1 | 2002 | 283 | 0.050 |
Why?
|
| Gene Deletion | 3 | 2014 | 2665 | 0.050 |
Why?
|
| Methylation | 2 | 2016 | 1084 | 0.050 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2022 | 174 | 0.050 |
Why?
|
| Histone Demethylases | 2 | 2016 | 323 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2024 | 42232 | 0.050 |
Why?
|
| Janus Kinase 1 | 2 | 1998 | 107 | 0.050 |
Why?
|
| Piperazines | 1 | 2012 | 2523 | 0.050 |
Why?
|
| Azacitidine | 1 | 2023 | 336 | 0.050 |
Why?
|
| Leukoplakia, Oral | 1 | 2021 | 77 | 0.050 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2002 | 178 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2012 | 3156 | 0.050 |
Why?
|
| Monitoring, Immunologic | 1 | 2021 | 98 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2016 | 691 | 0.050 |
Why?
|
| Amygdala | 1 | 2009 | 1354 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2009 | 1858 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2014 | 3600 | 0.050 |
Why?
|
| In Situ Hybridization | 2 | 2015 | 1900 | 0.050 |
Why?
|
| Risk Factors | 7 | 2019 | 74213 | 0.050 |
Why?
|
| Sucrose | 1 | 2021 | 158 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 2 | 2011 | 871 | 0.050 |
Why?
|
| DNA Methylation | 3 | 2019 | 4399 | 0.040 |
Why?
|
| RNA Interference | 3 | 2016 | 2832 | 0.040 |
Why?
|
| Graft Rejection | 2 | 2010 | 4446 | 0.040 |
Why?
|
| Administration, Oral | 3 | 2013 | 4021 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2022 | 662 | 0.040 |
Why?
|
| Fear | 1 | 2009 | 1477 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2016 | 17904 | 0.040 |
Why?
|
| Heart Transplantation | 2 | 2011 | 3233 | 0.040 |
Why?
|
| Chromosomes | 1 | 2023 | 578 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2015 | 561 | 0.040 |
Why?
|
| Toll-Like Receptors | 1 | 2023 | 589 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 2217 | 0.040 |
Why?
|
| Child | 7 | 2024 | 80158 | 0.040 |
Why?
|
| Splenectomy | 1 | 2001 | 391 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2020 | 3094 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2016 | 1126 | 0.040 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 39106 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 3 | 2016 | 4740 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 2018 | 5790 | 0.040 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2023 | 569 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2023 | 552 | 0.040 |
Why?
|
| Immunity, Humoral | 2 | 2017 | 606 | 0.040 |
Why?
|
| South America | 1 | 2019 | 179 | 0.040 |
Why?
|
| Leishmania donovani | 1 | 2000 | 68 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2013 | 7859 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2019 | 40 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2012 | 3537 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 3810 | 0.040 |
Why?
|
| Mice, Congenic | 1 | 2019 | 97 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2017 | 13446 | 0.040 |
Why?
|
| Chemokine CXCL9 | 1 | 2019 | 135 | 0.040 |
Why?
|
| Dendritic Spines | 1 | 2021 | 243 | 0.040 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2000 | 99 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2013 | 718 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2019 | 3397 | 0.040 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2011 | 419 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2001 | 376 | 0.040 |
Why?
|
| RNA, Double-Stranded | 1 | 2020 | 294 | 0.040 |
Why?
|
| Viral Load | 2 | 2022 | 3332 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 2019 | 214 | 0.040 |
Why?
|
| Peptides | 1 | 2010 | 4358 | 0.040 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2009 | 1642 | 0.040 |
Why?
|
| Leukopoiesis | 1 | 1998 | 54 | 0.040 |
Why?
|
| Cytokine Receptor gp130 | 1 | 1998 | 66 | 0.040 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2019 | 139 | 0.040 |
Why?
|
| Receptors, CXCR3 | 1 | 2019 | 238 | 0.040 |
Why?
|
| RNA, Antisense | 1 | 2018 | 136 | 0.040 |
Why?
|
| DNA Modification Methylases | 1 | 2018 | 210 | 0.040 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2019 | 177 | 0.040 |
Why?
|
| RNA, Messenger | 4 | 2015 | 12794 | 0.040 |
Why?
|
| Organogenesis | 1 | 2019 | 215 | 0.040 |
Why?
|
| Hydrogels | 1 | 2023 | 720 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2019 | 277 | 0.040 |
Why?
|
| Case-Control Studies | 4 | 2024 | 22176 | 0.040 |
Why?
|
| HIV-1 | 2 | 2012 | 6863 | 0.040 |
Why?
|
| Ferritins | 1 | 2020 | 598 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 3430 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2000 | 584 | 0.040 |
Why?
|
| Necrosis | 1 | 2001 | 1611 | 0.040 |
Why?
|
| Plasma Cells | 2 | 2011 | 599 | 0.040 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 3801 | 0.040 |
Why?
|
| Peptide Elongation Factor G | 1 | 2016 | 12 | 0.040 |
Why?
|
| Adrenalectomy | 1 | 2019 | 346 | 0.040 |
Why?
|
| Peptide Elongation Factor Tu | 1 | 2016 | 19 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1998 | 562 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2021 | 617 | 0.030 |
Why?
|
| Positron-Emission Tomography | 3 | 2022 | 6484 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2016 | 2707 | 0.030 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2016 | 38 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 346 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2020 | 1693 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2024 | 54423 | 0.030 |
Why?
|
| Sarcoma | 1 | 2007 | 1801 | 0.030 |
Why?
|
| Mechlorethamine | 1 | 2016 | 129 | 0.030 |
Why?
|
| Subrenal Capsule Assay | 1 | 2016 | 27 | 0.030 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2020 | 301 | 0.030 |
Why?
|
| Tissue Embedding | 1 | 2015 | 42 | 0.030 |
Why?
|
| Acute Disease | 1 | 2006 | 7237 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2016 | 198 | 0.030 |
Why?
|
| Data Mining | 1 | 2021 | 551 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2021 | 851 | 0.030 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2016 | 171 | 0.030 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2015 | 68 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2015 | 2919 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2024 | 9001 | 0.030 |
Why?
|
| Neurons, Afferent | 1 | 1998 | 498 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2022 | 2329 | 0.030 |
Why?
|
| Ovary | 1 | 2020 | 959 | 0.030 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2015 | 38 | 0.030 |
Why?
|
| Skin Transplantation | 2 | 2011 | 1083 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 3597 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2019 | 1341 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 316 | 0.030 |
Why?
|
| Cell Separation | 2 | 2011 | 1720 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2001 | 1071 | 0.030 |
Why?
|
| Bleomycin | 1 | 2016 | 494 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2022 | 2898 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 2015 | 178 | 0.030 |
Why?
|
| Hematopoiesis | 2 | 2014 | 2050 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2015 | 200 | 0.030 |
Why?
|
| Vinblastine | 1 | 2016 | 488 | 0.030 |
Why?
|
| Etoposide | 1 | 2016 | 634 | 0.030 |
Why?
|
| Cystectomy | 1 | 2019 | 634 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2016 | 496 | 0.030 |
Why?
|
| DNA Damage | 2 | 2016 | 2449 | 0.030 |
Why?
|
| Transplantation Immunology | 1 | 2016 | 532 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2016 | 931 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 1055 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2020 | 962 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2010 | 1119 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 802 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2014 | 248 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2014 | 163 | 0.030 |
Why?
|
| Aging | 1 | 2012 | 8710 | 0.030 |
Why?
|
| Weaning | 1 | 2013 | 103 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2013 | 111 | 0.030 |
Why?
|
| Intermediate Filaments | 1 | 2014 | 172 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 2009 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1998 | 1243 | 0.030 |
Why?
|
| Germ-Free Life | 1 | 2013 | 189 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2019 | 20568 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 473 | 0.030 |
Why?
|
| Litter Size | 1 | 2012 | 49 | 0.030 |
Why?
|
| Breeding | 1 | 2012 | 51 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 384 | 0.030 |
Why?
|
| Binding Sites | 2 | 2012 | 6056 | 0.030 |
Why?
|
| Visual Cortex | 1 | 2021 | 1108 | 0.030 |
Why?
|
| Organ Size | 1 | 1998 | 2254 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2015 | 392 | 0.030 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2013 | 99 | 0.030 |
Why?
|
| Thrombocythemia, Essential | 1 | 2014 | 113 | 0.030 |
Why?
|
| Hyperoxia | 1 | 2015 | 258 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 3420 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 431 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2013 | 189 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2019 | 2643 | 0.030 |
Why?
|
| Polycythemia Vera | 1 | 2014 | 161 | 0.030 |
Why?
|
| HEK293 Cells | 2 | 2013 | 4281 | 0.030 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2016 | 304 | 0.030 |
Why?
|
| RNA, Viral | 2 | 2012 | 2846 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 2013 | 777 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 705 | 0.030 |
Why?
|
| Organisms, Genetically Modified | 1 | 2012 | 63 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2012 | 105 | 0.030 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2013 | 207 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2012 | 162 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 2650 | 0.020 |
Why?
|
| Lysine | 1 | 2016 | 993 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2012 | 160 | 0.020 |
Why?
|
| E2F Transcription Factors | 1 | 2012 | 269 | 0.020 |
Why?
|
| Duffy Blood-Group System | 1 | 2012 | 58 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2016 | 744 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 657 | 0.020 |
Why?
|
| Death | 1 | 2016 | 676 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 95 | 0.020 |
Why?
|
| Benzoquinones | 1 | 2012 | 198 | 0.020 |
Why?
|
| Soybean Oil | 1 | 2012 | 139 | 0.020 |
Why?
|
| Time Factors | 3 | 2019 | 39969 | 0.020 |
Why?
|
| Plant Oils | 1 | 2012 | 198 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 3514 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2011 | 2057 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2012 | 265 | 0.020 |
Why?
|
| Receptors, Cell Surface | 2 | 2012 | 2822 | 0.020 |
Why?
|
| Lung | 1 | 2010 | 10002 | 0.020 |
Why?
|
| Age Factors | 3 | 2017 | 18399 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2016 | 1561 | 0.020 |
Why?
|
| Receptors, Calcitriol | 1 | 2014 | 360 | 0.020 |
Why?
|
| Crystallization | 1 | 2012 | 534 | 0.020 |
Why?
|
| Karyotyping | 1 | 2013 | 1171 | 0.020 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2012 | 225 | 0.020 |
Why?
|
| Foreskin | 1 | 2011 | 33 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2012 | 257 | 0.020 |
Why?
|
| Leupeptins | 1 | 2011 | 113 | 0.020 |
Why?
|
| Immune System | 1 | 2016 | 796 | 0.020 |
Why?
|
| Genes, Immunoglobulin | 1 | 2011 | 285 | 0.020 |
Why?
|
| Blood Cells | 1 | 2013 | 305 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2019 | 1824 | 0.020 |
Why?
|
| Symbiosis | 1 | 2013 | 294 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2012 | 271 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2011 | 92 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2012 | 342 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 976 | 0.020 |
Why?
|
| Lactams, Macrocyclic | 1 | 2012 | 318 | 0.020 |
Why?
|
| North America | 1 | 2014 | 1276 | 0.020 |
Why?
|
| 5-Methylcytosine | 1 | 2011 | 148 | 0.020 |
Why?
|
| United States | 5 | 2019 | 72340 | 0.020 |
Why?
|
| Protein Stability | 1 | 2012 | 578 | 0.020 |
Why?
|
| Immunologic Factors | 2 | 2010 | 1590 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 629 | 0.020 |
Why?
|
| Interleukin-6 | 2 | 2010 | 3208 | 0.020 |
Why?
|
| Tensile Strength | 1 | 2011 | 330 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 2571 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 3713 | 0.020 |
Why?
|
| Glucose | 1 | 2022 | 4347 | 0.020 |
Why?
|
| CpG Islands | 1 | 2014 | 1230 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2011 | 223 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 1749 | 0.020 |
Why?
|
| Brain | 3 | 2016 | 27121 | 0.020 |
Why?
|
| Cullin Proteins | 1 | 2011 | 179 | 0.020 |
Why?
|
| Paraproteinemias | 1 | 2012 | 248 | 0.020 |
Why?
|
| Birth Weight | 1 | 1998 | 2103 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 11122 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2010 | 621 | 0.020 |
Why?
|
| Benzylamines | 1 | 2010 | 247 | 0.020 |
Why?
|
| Genes, jun | 1 | 2009 | 69 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2009 | 20 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 883 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2010 | 326 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2016 | 1608 | 0.020 |
Why?
|
| Kinetics | 2 | 2012 | 6374 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2010 | 246 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2011 | 238 | 0.020 |
Why?
|
| Serum | 1 | 2011 | 209 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 866 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 1787 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2010 | 250 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2016 | 1742 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 293 | 0.020 |
Why?
|
| Bloom Syndrome | 1 | 2009 | 10 | 0.020 |
Why?
|
| Dysgerminoma | 1 | 2009 | 66 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 277 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 1646 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 698 | 0.020 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2009 | 25 | 0.020 |
Why?
|
| Immunoglobulin Switch Region | 1 | 2009 | 44 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2010 | 375 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2012 | 350 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2015 | 1526 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 2009 | 216 | 0.020 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2010 | 111 | 0.020 |
Why?
|
| Internationality | 1 | 2014 | 1001 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2010 | 487 | 0.020 |
Why?
|
| Inflammation | 2 | 2023 | 10774 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2010 | 677 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 3792 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 2139 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2009 | 158 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2012 | 1529 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3826 | 0.020 |
Why?
|
| DNA Primers | 1 | 2013 | 2820 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2009 | 452 | 0.020 |
Why?
|
| Respiration | 1 | 2015 | 1656 | 0.020 |
Why?
|
| Germinoma | 1 | 2009 | 132 | 0.020 |
Why?
|
| Methylcholanthrene | 1 | 2007 | 31 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 1118 | 0.020 |
Why?
|
| Carrier Proteins | 2 | 2011 | 4937 | 0.020 |
Why?
|
| Patient Selection | 1 | 2020 | 4244 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2009 | 740 | 0.020 |
Why?
|
| Leukemia | 1 | 2016 | 1522 | 0.020 |
Why?
|
| Genes, RAG-1 | 1 | 2007 | 67 | 0.020 |
Why?
|
| Immunity, Active | 1 | 2007 | 58 | 0.020 |
Why?
|
| Seminoma | 1 | 2009 | 134 | 0.020 |
Why?
|
| Teratoma | 1 | 2011 | 404 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 2009 | 295 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 641 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 678 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1998 | 4142 | 0.020 |
Why?
|
| Models, Biological | 2 | 2016 | 9469 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 1990 | 0.020 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2009 | 195 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 1079 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2010 | 652 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2007 | 138 | 0.020 |
Why?
|
| Long-Term Potentiation | 1 | 2009 | 293 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 794 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 2016 | 0.020 |
Why?
|
| Neutropenia | 1 | 2012 | 885 | 0.020 |
Why?
|
| DNA Repair | 1 | 2016 | 2046 | 0.020 |
Why?
|
| Albumins | 1 | 2010 | 575 | 0.020 |
Why?
|
| Uterus | 1 | 2011 | 649 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 306 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2010 | 636 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 2273 | 0.020 |
Why?
|
| Living Donors | 1 | 2011 | 641 | 0.020 |
Why?
|
| Caspases | 1 | 2010 | 879 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 2065 | 0.020 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 733 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 1612 | 0.020 |
Why?
|
| Infant | 2 | 2024 | 36193 | 0.020 |
Why?
|
| Microvessels | 1 | 2011 | 577 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 3606 | 0.020 |
Why?
|
| Genes, ras | 1 | 2009 | 654 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2011 | 1687 | 0.020 |
Why?
|
| Endothelium | 1 | 2009 | 765 | 0.020 |
Why?
|
| Smoking | 2 | 2015 | 9053 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2011 | 4174 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2011 | 1007 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 1229 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 1679 | 0.020 |
Why?
|
| Mesoderm | 1 | 2009 | 674 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 2209 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 682 | 0.020 |
Why?
|
| Epigenomics | 1 | 2011 | 943 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 1552 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2007 | 513 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 1120 | 0.020 |
Why?
|
| Myocardium | 1 | 1998 | 4725 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2009 | 799 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 4352 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 1601 | 0.010 |
Why?
|
| Rabbits | 1 | 2011 | 4772 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2010 | 1187 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2010 | 2927 | 0.010 |
Why?
|
| Liver | 1 | 2000 | 7528 | 0.010 |
Why?
|
| Cholesterol | 1 | 2013 | 2905 | 0.010 |
Why?
|
| Chromatin | 1 | 2016 | 2961 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2009 | 1519 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 3779 | 0.010 |
Why?
|
| Medulloblastoma | 1 | 2009 | 678 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4811 | 0.010 |
Why?
|
| Causality | 1 | 2009 | 1242 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 1651 | 0.010 |
Why?
|
| Virus Replication | 1 | 2011 | 2435 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 1964 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2010 | 1732 | 0.010 |
Why?
|
| Cell Division | 1 | 2010 | 4465 | 0.010 |
Why?
|
| Colon | 1 | 2011 | 1792 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2009 | 1173 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 1935 | 0.010 |
Why?
|
| Autophagy | 1 | 2010 | 1327 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2007 | 1060 | 0.010 |
Why?
|
| Stem Cells | 1 | 2014 | 3524 | 0.010 |
Why?
|
| DNA Replication | 1 | 2009 | 1418 | 0.010 |
Why?
|
| Pancreas | 1 | 2008 | 1691 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 1899 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2011 | 5439 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 2898 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 2048 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 2915 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2009 | 2693 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 6312 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2010 | 2161 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 26129 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2009 | 1376 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 12059 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2015 | 3816 | 0.010 |
Why?
|
| Genome, Human | 1 | 2012 | 4425 | 0.010 |
Why?
|
| Kidney | 1 | 2014 | 7048 | 0.010 |
Why?
|
| Computational Biology | 1 | 2011 | 3517 | 0.010 |
Why?
|
| Nanoparticles | 1 | 2010 | 1958 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2007 | 2302 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 2492 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 23996 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 7406 | 0.010 |
Why?
|
| Phosphotyrosine | 1 | 1998 | 456 | 0.010 |
Why?
|
| src Homology Domains | 1 | 1998 | 361 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2010 | 9647 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 4176 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2010 | 3549 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2012 | 9319 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 1996 | 151 | 0.010 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 1996 | 93 | 0.010 |
Why?
|
| Sex Factors | 1 | 2009 | 10554 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 13255 | 0.010 |
Why?
|
| Skin | 1 | 2009 | 4484 | 0.010 |
Why?
|
| DNA Probes | 1 | 1996 | 541 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 1996 | 341 | 0.010 |
Why?
|
| Algorithms | 1 | 2014 | 14033 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1996 | 921 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1996 | 2206 | 0.000 |
Why?
|
| Rats | 1 | 1996 | 23741 | 0.000 |
Why?
|